Heart patients exposed to phthalates—a group of chemicals used as plasticizers in the manufacture of plastic medical products—during invasive procedures may be at risk for serious electrophysiological abnormalities, according to a new study.

Gadobutrol, sold by Bayer under the brand name Gadavist, became the first FDA-approved contrast agent for use in cardiac magnetic resonance imaging on July 15.

Sometimes a move in the right direction starts with a good hard look in the rearview mirror, then breaking it off to start anew with greater wisdom.

Cardiologists discuss the questions and concerns swirling around the thriving wearables market as patients strap on a variety of smart devices and expect their physicians to catch up.

Though it’s guideline-directed to assess acute MI patients with echocardiography following a heart attack, hospitals that follow that rule incur greater costs and lengths of stay than those that employ echo more selectively, a recent study found.

Medical directors of cardiac catheterization and EP labs receive three to four times the amount of money from pharmaceutical companies and device manufacturers as other interventional cardiologists in the same zip code, according to a JAMA Internal Medicine study.

A team of University of Texas at Austin researchers are looking to replace the decades-old electrocardiography process with a more comprehensive, streamlined way to monitor heart health: e-tattoos.

The Cardiovascular Research Foundation is partnering with VEITHsymposium, one of the largest annual meetings in vascular medicine, to enhance conference material at both VEITHsymposium and the CRF’s yearly Transcatheter Cardiovascular Therapeutics conference, the groups announced June 20.